Clinical Response, Radiological Response
Conditions
Keywords
multidrug-resistant Acinetobacter baumannii, ventilator-associated pneumonia, intensive care unit
Brief summary
This study aims to evaluate clinical outcomes of colistin versus colistin in combination with cefoperazone-sulbactam for patients with MDR-AB VAP treatment.
Detailed description
MDR-AB (multidrug-resistant Acinetobacter baumannii) has been an increasingly common cause of ventilator-associated pneumonia (VAP) in intensive care unit (ICU). Colistin remains the last available antibiotic choice. Unfortunately, colistin monotherapy is often inadequate for microbiologic eradication and a risk factor of nephrotoxicity and for heteroresistance.
Interventions
DRUGcolistin plus cefoperazone-sulbactam combination group
Combination therapy
DRUGColistin
Monotherapy
Sponsors
Shaheed Mohtarma Benazir Bhutto Institue of Trauma
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients with a diagnosis of VAP due to A. baumannii
Exclusion criteria
* patients who had polymicrobial VAP * Patients with pre-existing severe renal failure and/or abnormal liver function tests * Patients allergic to colistin or cefoperazone-sulbactam
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical response | within one week | Clinical response was defined as observable improvement in the patient's clinical signs/symptoms, including absence of fever (temp\<38ºC) for three consecutive days or more, and decreasing amount and purulence of tracheal secretions |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Radiological response | within one week | Radiological response was defined as improvement/resolution of pulmonary infiltrates, as noted on chest x-rays following treatment. |
Countries
Pakistan
Outcome results
None listed